Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free IFRX Stock Alerts

InflaRx (IFRX) Financials

InflaRx logo
$2.05 -0.01 (-0.49%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$2.08 +0.03 (+1.22%)
As of 07/10/2026 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for InflaRx

Annual Income Statements for InflaRx

This table shows InflaRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.34 -9.40 -29 -34 -60 -42 -44 -34 -62 -53 -57
Consolidated Net Income / (Loss)		 -5.34 -9.40 -29 -34 -60 -42 -52 -32 -47 -48 -54
Net Income / (Loss) Continuing Operations		 -4.11 -9.40 -29 -34 -60 -42 -52 -34 -62 -53 -57
Total Pre-Tax Income 		-5.34 -9.40 -29 -41 -60 -42 -52 -34 -62 -53 -57
Total Operating Income		 -4.11 -7.25 -23 -41 -61 -42 -54 -55 -64 -60 -60
Total Gross Profit		 0.00 -7.49 0.16 2.50 3.19 1.05 0.00 0.00 -0.52 -3.26 -8.49
Total Revenue		 0.00 0.00 0.16 2.50 3.19 1.08 0.00 0.65 0.07 0.17 0.03
Operating Revenue		 - - 0.16 2.50 3.19 1.08 0.00 0.65 0.07 0.17 0.03
Total Cost of Revenue		 0.00 0.01 0.00 0.00 0.00 0.03 0.00 0.00 0.59 3.43 8.53
Operating Cost of Revenue		 - 0.01 - - - 0.03 0.00 0.00 0.59 3.43 8.53
Total Operating Expenses		 4.11 7.24 23 43 64 43 52 56 64 57 51
Selling, General & Admin Expense		 0.48 1.94 6.17 15 14 10 14 16 14 13 16
Marketing Expense		 - - - - - - 0.00 0.00 4.43 6.99 5.26
Research & Development Expense		 3.78 5.55 17 29 50 31 40 40 45 37 30
Other Operating Expenses / (Income)		 -0.15 -0.25 0.01 0.01 0.10 0.96 -2.22 0.00 0.00 0.00 0.02
Total Other Income / (Expense), net		 -1.23 -2.15 -5.77 0.23 0.47 0.12 0.11 21 2.48 7.19 3.10
Interest Expense		 1.24 2.16 5.91 0.00 -0.02 - 0.03 0.05 0.04 0.02 0.05
Interest & Investment Income		 0.01 0.00 - - - - 0.12 - 4.21 3.31 2.17
Other Income / (Expense), net		 0.00 0.00 0.14 0.23 0.45 0.12 0.01 21 -1.69 3.91 0.98
Income Tax Expense		 0.00 - - -6.44 -0.78 0.00 0.00 0.00 0.00 0.01 0.01
Basic Earnings per Share		 ($2.10) ($3.80) - ($1.19) ($2.05) - ($1.10) ($0.72) ($0.86) ($0.81) ($0.80)
Weighted Average Basic Shares Outstanding		 - 2.49K 9.41M 25.10M 26.00M -1.26 41.63M 44.70M 54.94M 58.92M 67.29M
Diluted Earnings per Share		 ($2.10) ($3.80) - ($1.19) ($2.05) - - ($0.72) ($0.86) ($0.81) ($0.80)
Weighted Average Diluted Shares Outstanding		 - 2.36M 9.41M 25.10M 26.00M 27.06M - 44.70M 58.88M 59.35M 72.29M
Weighted Average Basic & Diluted Shares Outstanding		 - 2.49K 9.41M 25.10M 26.00M 27.06M - 44.70M 58.88M 59.35M 72.29M

Quarterly Income Statements for InflaRx

No quarterly income statements for InflaRx are available.

Annual Cash Flow Statements for InflaRx

This table details how cash moves in and out of InflaRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.61 27 158 110 -27 -45 102 -30 22 -40 -34
Net Cash From Operating Activities		 -3.61 -5.25 27 45 -51 -46 -48 -32 -36 -40 -58
Net Cash From Continuing Operating Activities		 -3.61 -5.24 27 45 -51 -46 -48 -32 -36 -40 -58
Net Income / (Loss) Continuing Operations		 -5.34 -9.40 -5.76 8.81 -64 -42 -49 -29 -45 -40 -50
Consolidated Net Income / (Loss)		 -5.34 -9.40 -5.76 8.81 -64 -42 -49 -29 -45 -40 -50
Depreciation Expense		 0.04 0.03 0.09 0.20 0.74 0.87 0.76 0.64 0.63 0.50 0.49
Non-Cash Adjustments To Reconcile Net Income		 1.26 3.18 29 35 8.27 1.80 -0.00 -0.07 0.33 0.47 -1.06
Changes in Operating Assets and Liabilities, net		 0.42 0.94 3.50 1.54 3.55 -6.96 0.36 -3.84 7.73 -0.60 -7.04
Net Cash From Investing Activities		 0.00 -0.06 -0.18 8.22 117 26 81 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 -0.06 -0.18 8.22 117 26 81 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.00 32 131 57 -0.33 11 70 2.07 59 0.40 39
Net Cash From Continuing Financing Activities		 0.00 32 131 57 0.00 11 70 2.07 59 0.40 24
Repayment of Debt		 - - 0.00 0.00 - -0.45 -0.41 -0.39 -0.41 -0.40 -0.42
Issuance of Common Equity		 - 0.00 98 56 0.00 11 69 2.46 59 0.80 24
Other Financing Activities, net		 - - 0.00 0.52 - 0.61 1.15 0.00 0.26 0.00 0.00
Other Net Changes in Cash		 - - - - -93 - -0.04 -0.17 -0.09 -0.05 -0.14
Cash Interest Paid		 -0.01 - 0.00 0.00 -0.02 0.03 0.03 0.05 0.04 0.02 0.04
Cash Interest Received		 0.00 - 0.08 1.92 3.37 1.47 1.21 1.38 1.92 2.32 2.04

Quarterly Cash Flow Statements for InflaRx

No quarterly cash flow statements for InflaRx are available.

Annual Balance Sheets for InflaRx

This table presents InflaRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 31 149 182 136 108 110 133 79 65
Total Current Assets		 31 149 181 134 105 34 121 74 27
Cash & Equivalents		 31 148 63 37 32 17 14 19 19
Inventories, net		 - - - - - 0.00 13 - 0.00
Current Deferred & Refundable Income Taxes		 - - - 1.27 1.73 1.53 4.19 1.80 1.68
Other Current Assets		 - 0.84 118 95 72 15 4.47 5.28 6.75
Plant, Property, & Equipment, net		 0.00 0.21 0.71 0.65 0.50 0.35 0.32 0.27 0.34
Total Noncurrent Assets		 0.28 0.07 0.49 2.26 1.86 75 97 4.20 37
Intangible Assets		 0.01 0.05 0.26 0.51 0.43 0.15 0.08 - 0.05
Other Noncurrent Operating Assets		 0.28 0.02 0.24 1.75 1.43 75 97 4.20 37
Total Liabilities & Shareholders' Equity		 31 149 182 136 108 110 133 79 65
Total Liabilities		 58 5.75 8.95 16 13 15 19 15 16
Total Current Liabilities		 1.84 5.73 8.88 16 12 13 19 15 14
Accounts Payable		 1.61 5.37 7.62 14 10 5.34 13 12 6.34
Other Current Liabilities		 0.22 - 0.00 0.75 0.58 7.20 3.61 0.73 7.53
Total Noncurrent Liabilities		 56 0.02 0.08 0.41 0.31 2.50 0.87 0.45 2.16
Noncurrent Employee Benefit Liabilities		 - - - - - 1.40 - - 1.37
Other Noncurrent Operating Liabilities		 - - 0.08 0.04 0.04 1.10 0.04 0.04 0.80
Total Equity & Noncontrolling Interests		 -27 143 173 120 95 189 113 64 49
Total Preferred & Common Equity		 -27 143 173 120 95 189 113 64 49
Total Common Equity		 -27 -51 -68 -117 -174 189 -256 -283 49
Common Stock		 0.03 3.43 3.57 3.52 4.14 5.74 7.82 7.37 10
Retained Earnings		 -28 -62 -93 -151 -206 -260 -317 -344 -443
Other Equity Adjustments		 1.77 7.48 21 31 28 444 52 53 482

Quarterly Balance Sheets for InflaRx

No quarterly balance sheets for InflaRx are available.

Annual Metrics And Ratios for InflaRx

This table displays calculated financial ratios and metrics derived from InflaRx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 23,812,100.00 23,812,100.00 26,105,255.00 28,228,415.00 44,203,763.00 44,703,763.00 58,883,272.00 58,883,272.00 58,883,272.00
DEI Adjusted Shares Outstanding		 0.00 0.00 23,812,100.00 23,812,100.00 26,105,255.00 28,228,415.00 44,203,763.00 44,703,763.00 58,883,272.00 58,883,272.00 58,883,272.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.22 -1.43 -2.29 -1.47 -0.99 -0.76 -1.05 -0.90 -0.96
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -2.88 -5.07 -16 -29 -43 -29 -38 -39 -45 -42 -42
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -20.52% -39.38% -66.02% -85.79%
Earnings before Interest and Taxes (EBIT)		 -4.11 -7.25 -23 -41 -61 -42 -54 -34 -66 -56 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.06 -7.21 -23 -40 -60 -41 -53 -33 -65 -56 -58
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.50 -13 -143 -16 -9.37 26 -116 -68 61 -75
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -1.57 -4.61 110 83 64 0.00 77 100 -3.16 30
Increase / (Decrease) in Invested Capital		 0.00 -1.57 -3.04 114 -26 -20 -64 77 23 -103 33
Book Value per Share		 $0.00 ($10,870.81) ($5.39) ($2.87) ($4.49) ($6.66) $0.00 $4.28 ($5.73) ($4.81) $0.72
Tangible Book Value per Share		 $0.00 ($10,872.92) ($5.39) ($2.88) ($4.51) ($6.68) $0.00 $4.27 ($5.73) ($4.81) $0.72
Total Capital		 0.00 -27 143 173 121 95 0.00 189 114 64 49
Total Debt		 0.00 0.00 0.00 0.00 0.37 0.27 0.00 0.00 0.82 0.41 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.37 0.27 0.00 0.00 0.82 0.41 0.00
Net Debt		 0.00 -31 -148 -63 -37 -31 0.00 -17 -13 -19 -19
Capital Expenditures (CapEx)		 0.00 0.06 0.18 0.92 -0.67 0.12 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.56 -4.89 109 81 61 0.00 4.16 88 40 -5.45
Debt-free Net Working Capital (DFNWC)		 0.00 29 143 172 118 93 0.00 22 102 60 13
Net Working Capital (NWC)		 0.00 29 143 172 118 93 0.00 22 102 60 13
Net Nonoperating Expense (NNE)		 2.47 4.33 13 5.57 17 12 14 -7.24 2.19 5.44 12
Net Nonoperating Obligations (NNO)		 0.00 25 -148 -63 -37 -31 0.00 -112 -13 -67 -19
Total Depreciation and Amortization (D&A)		 0.04 0.03 0.09 0.20 0.74 0.87 0.76 0.64 0.63 0.50 0.49
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.60) $0.00 $0.00 ($1.26) $0.00 $0.00 ($0.78) ($0.81) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 23.81M 0.00 26.11M 28.23M 0.00 0.00 54.94M 58.92M 67.29M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.60) $0.00 $0.00 ($1.26) $0.00 $0.00 $0.00 ($0.81) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 23.81M 0.00 26.11M 27.06M 0.00 0.00 58.88M 59.35M 72.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.60) $0.00 $0.00 ($1.26) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 23.81M 0.00 26.00M 28.23M 0.00 0.00 58.88M 59.35M 72.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.88 -5.07 -16 -29 -43 -29 -38 -39 -45 -42 -42
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for InflaRx

No quarterly metrics and ratios for InflaRx are available.


Financials Breakdown Chart

InflaRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, InflaRx's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

InflaRx's net income appears to be on an upward trend, with a most recent value of -$53.56 million in 2025, rising from -$5.34 million in 2015. The previous period was -$47.68 million in 2024. View InflaRx's forecast to see where analysts expect InflaRx to go next.

InflaRx's total operating income in 2025 was -$59.77 million, based on the following breakdown:
  • Total Gross Profit: -$8.49 million
  • Total Operating Expenses: $51.28 million

Over the last 10 years, InflaRx's total revenue changed from $0.00 in 2015 to $34.42 thousand in 2025, a change of 3,442,300.0%.

InflaRx's total liabilities were at $16.03 million at the end of 2025, a 6.1% increase from 2024, and a 72.4% decrease since 2016.

In the past 8 years, InflaRx's cash and equivalents has ranged from $14.12 million in 2023 to $148.09 million in 2017, and is currently $18.80 million as of their latest financial filing in 2025.

Over the last 10 years, InflaRx's book value per share changed from 0.00 in 2015 to 0.72 in 2025, a change of 72.5%.


Related Companies

Financial statements for NASDAQ:IFRX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel